THE JAMES GRAHAM BROWN CANCER CENTER at the University of Louisville received a three-year, $5.5 million grant to develop new treatments and vaccines for various forms of cancer from the Leona M. and Harry B. Helmsley Charitable Trust.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
